Lyell Immunopharma: Peers

The FY2023 (Dec) proxy of Lyell Immunopharma names 21 peer companies for pay. Among Lyell Immunopharma and these peers, CEO pay was 10th highest of 12 and total shareholder return was 11th highest of 12.

10th highest of 12in Lyell Immunopharma and its pay peers, FY2023 (Dec) by CEO pay:

$1.2M$19.8M

11th highest of 12in Lyell Immunopharma and its pay peers, FY2023 (Dec) by total shareholder return:

$4$208

Pay peer group, FY2023 (Dec) proxy

Relay Therapeutics
Allogene Therapeutics
CRISPR Therapeutics AG
Intellia Therapeutics
Revolution Medicines
Arcus Biosciences
Beam Therapeutics
Iovance Biotherapeutics
Fate Therapeutics
Editas Medicine
ImmunityBio
Atara BiotherapeuticsNot disclosedNot disclosed
Century TherapeuticsNot disclosedNot disclosed
ErascaNot disclosedNot disclosed
IGM BiosciencesNot disclosedNot disclosed
Instil BioNot disclosedNot disclosed
NGM BiopharmaceuticalsNot disclosedNot disclosed
Prometheus BiosciencesNot disclosedNot disclosed
Sana BiotechnologyNot disclosedNot disclosed
Turning Point TherapeuticsNot disclosedNot disclosed
Zentalis PharmaceuticalsNot disclosedNot disclosed
21 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.